{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:40:38Z","timestamp":1793500838057,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.pnpbp.2020.110096","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T05:22:56Z","timestamp":1599369776000},"page":"110096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Endocannabinoid system in psychotic and mood disorders, a review of human studies"],"prefix":"10.1016","volume":"106","author":[{"given":"Ranjini","family":"Garani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pnpbp.2020.110096_bb0005","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1021\/cr0782067","article-title":"Enzymatic pathways that regulate endocannabinoid signaling in the nervous system","volume":"108","author":"Ahn","year":"2008","journal-title":"Chem. Rev."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0010","first-page":"1","article-title":"Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids","author":"Appiah-Kusi","year":"2019","journal-title":"Psychol. Med."},{"issue":"13","key":"10.1016\/j.pnpbp.2020.110096_bb0015","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/npp.2013.165","article-title":"Peripheral endocannabinoid system dysregulation in first-episode psychosis","volume":"38","author":"Bioque","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110096_bb0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2016.01.002","article-title":"Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis","volume":"75","author":"Bioque","year":"2016","journal-title":"J. Psychiatr. Res."},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110096_bb0025","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamapsychiatry.2019.1427","article-title":"In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis","volume":"76","author":"Borgan","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpsychires.2016.12.001","article-title":"Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: evidence for defective immunomodulatory mechanisms","volume":"87","author":"de Campos-Carli","year":"2017","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110096_bb0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2019.02.002","article-title":"ABHD6: its place in endocannabinoid signaling and beyond","volume":"40","author":"Cao","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.pnpbp.2020.110096_bb0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.psychres.2016.08.055","article-title":"Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia","volume":"245","author":"Chase","year":"2016","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110096_bb0050","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpsychires.2012.03.021","article-title":"Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear","volume":"46","author":"Choi","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.psyneuen.2018.03.009","article-title":"Circulating endocannabinoids and affect regulation in human subjects","volume":"92","author":"Coccaro","year":"2018","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110096_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0065","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2017.01.022","article-title":"A preliminary study of endocannabinoid system regulation in psychosis: distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia","volume":"188","author":"D\u2019Addario","year":"2017","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110096_bb0070","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110096_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-2-5","article-title":"Endocannabinoid signalling in the blood of patients with schizophrenia","volume":"2","author":"De Marchi","year":"2003","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110096_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","article-title":"Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use","volume":"103","author":"Dean","year":"2001","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.pnpbp.2020.110096_bb0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12264-007-0051-9","article-title":"No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia","volume":"23","author":"Deng","year":"2007","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fpsyt.2012.00085","article-title":"Plasma Endocannabinoid alterations in individuals with substance use disorder are dependent on the \u201cMirror effect\u201d of schizophrenia","volume":"3","author":"Desfoss\u00e9s","year":"2012","journal-title":"Front Psychiatr."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110096_bb0095","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110096_bb0100","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/npp.2010.75","article-title":"Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder","volume":"35","author":"Eggan","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2020.110096_bb0105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.schres.2014.04.028","article-title":"Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia","volume":"156","author":"Ferretjans","year":"2014","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110096_bb0110","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110096_bb0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2007-993211","article-title":"Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report","volume":"41","author":"Hill","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110096_bb0120","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","article-title":"Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress","volume":"34","author":"Hill","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2020.110096_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.irn.2015.10.001","article-title":"The Endocannabinoid Signaling system in the CNS: a primer","volume":"125","author":"Hillard","year":"2015","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroscience.2011.11.020","article-title":"Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence","volume":"204","author":"Hillard","year":"2012","journal-title":"Neuroscience"},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110096_bb0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.biopsych.2018.07.009","article-title":"Decreased cannabinoid CB(1) receptors in male tobacco smokers examined with positron emission tomography","volume":"84","author":"Hirvonen","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110096_bb0140","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.mp.4001376","article-title":"Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims","volume":"9","author":"Hungund","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110096_bb0145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.euroneuro.2018.12.014","article-title":"A systematic review of phytocannabinoid exposure on the endocannabinoid system: implications for psychosis","volume":"29","author":"Jacobson","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2020.110096_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2012.07.021","article-title":"Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia","volume":"141","author":"Jenko","year":"2012","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110096_bb0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2183\/pjab.90.235","article-title":"Control of synaptic function by endocannabinoid-mediated retrograde signaling","volume":"90","author":"Kano","year":"2014","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110096_bb0160","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nm.f.1869","article-title":"Endocannabinoid signaling as a synaptic circuit breaker in neurological disease","volume":"14","author":"Katona","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0165","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-neuro-062111-150420","article-title":"Multiple functions of endocannabinoid signaling in the brain","volume":"35","author":"Katona","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110096_bb0170","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","article-title":"Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression","volume":"114","author":"Koethe","year":"2007","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110096_bb0175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110096_bb0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15622975.2018.1449966","article-title":"Familial abnormalities of endocannabinoid signaling in schizophrenia","volume":"20","author":"Koethe","year":"2019","journal-title":"World J. Biol. Psychiatr."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110096_bb0185","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00406-017-0789-7","article-title":"Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study","volume":"267","author":"Kranaster","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110096_bb0190","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"Leweke","year":"1999","journal-title":"Neuroreport"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2020.110096_bb0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110096_bb0200","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110096_bb0205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"168","author":"Mackie","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bcp.2018.08.012","article-title":"Selective up-regulation of cannabinoid CB(1) receptor coupling to Go-proteins in suicide victims with mood disorders","volume":"157","author":"Mato","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.pnpbp.2020.110096_bb0215","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.biopsych.2016.04.015","article-title":"Positron emission tomography studies on cannabinoid receptor type 1 in schizophrenia","volume":"79","author":"Mihov","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110096_bb0220","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamapsychiatry.2019.0970","article-title":"Measuring disturbance of the Endocannabinoid system in psychosis: a systematic review and meta-analysis","volume":"76","author":"Minichino","year":"2019","journal-title":"JAMA Psychiatr."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110096_bb0225","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1007\/s12035-018-0876-4","article-title":"Accessing gene expression in treatment-resistant schizophrenia","volume":"55","author":"Moretti","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2020.110096_bb0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2013.06.013","article-title":"Quantification of endocannabinoids in postmortem brain of schizophrenic subjects","volume":"148","author":"Muguruza","year":"2013","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110096_bb0235","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/0269881119857205","article-title":"Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia","volume":"33","author":"Muguruza","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110096_bb0240","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","article-title":"Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia","volume":"172","author":"Newell","year":"2006","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0245","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1038\/srep07796","article-title":"Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder","volume":"5","author":"Ogawa","year":"2015","journal-title":"Sci. Rep."},{"issue":"168","key":"10.1016\/j.pnpbp.2020.110096_bb0250","first-page":"1","article-title":"Pharmacological actions of cannabinoids","author":"Pertwee","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2020.110096_bb0255","first-page":"S163","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2020.110096_bb0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1054\/plef.2001.0341","article-title":"Cannabinoid receptors and their ligands","volume":"66","author":"Pertwee","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110096_bb3000","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110096_bb0265","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/0269881107083816","article-title":"Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy","volume":"22","author":"Potvin","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.pnpbp.2020.110096_bb0270","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","article-title":"Reduced brain cannabinoid receptor availability in schizophrenia","volume":"79","author":"Ranganathan","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2020.110096_bb0275","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/15622975.2016.1246750","article-title":"Association of anandamide with altered binocular depth inversion illusion in schizophrenia","volume":"18","author":"Reuter","year":"2017","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0280","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.neuropharm.2019.02.026","article-title":"Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants","volume":"149","author":"Romero-Sanchiz","year":"2019","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110096_bb0285","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/febs.12152","article-title":"Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways","volume":"280","author":"Ueda","year":"2013","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110096_bb0290","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment","volume":"206","author":"Uriguen","year":"2009","journal-title":"Psychopharmacology"},{"issue":"5746","key":"10.1016\/j.pnpbp.2020.110096_bb0295","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110096_bb0300","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.biopsych.2015.06.015","article-title":"The role of Endocannabinoid Signaling in cortical inhibitory neuron dysfunction in schizophrenia","volume":"79","author":"Volk","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.pnpbp.2020.110096_bb0305","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1176\/appi.ajp.2010.10030318","article-title":"Alterations in metabotropic glutamate receptor 1\u03b1 and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia","volume":"167","author":"Volk","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110096_bb0310","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2013.02.038","article-title":"Endocannabinoid metabolism in the prefrontal cortex in schizophrenia","volume":"147","author":"Volk","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110096_bb0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2020.110096_bb0320","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpsychires.2018.04.002","article-title":"Alterations of eicosanoids and related mediators in patients with schizophrenia","volume":"102","author":"Wang","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110096_bb0325","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.biopsych.2020.03.003","article-title":"Imaging brain fatty acid amide hydrolase in untreated patients with psychosis","volume":"88","author":"Watts","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110096_bb0330","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","article-title":"Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR","volume":"52","author":"Wong","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.pnpbp.2020.110096_bb0335","first-page":"1","article-title":"Lipidome alterations in human prefrontal cortex during development, aging, and cognitive disorders","author":"Yu","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110096_bb0340","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","article-title":"Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia","volume":"28","author":"Zavitsanou","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:59:25Z","timestamp":1759521565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584620304127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":69,"alternative-id":["S0278584620304127"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110096","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocannabinoid system in psychotic and mood disorders, a review of human studies","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110096"}}